Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate except neuroendocrine carcinoma including small cell carcinoma~* Disease progressed on or after prior docetaxel-containing chemotherapy~* Prior 1 or 2 cytotoxic chemotherapy regimens for metastatic castration-resistant prostate cancer, at least 1 of which contains docetaxel~* Documented prostate cancer progression as documented by prostate specific antigen progression according to Prostate Specific Antigen Working Group criteria or radiographic progression in soft tissue or bone~* Surgically or medically castrated, with serum testosterone level \<50 ng/dL (1.7 nmol/L)~* Eastern Cooperative Oncology Group performance status score of \<=2~* Protocol-defined laboratory values~* Agrees to protocol-defined use of effective contraception~Exclusion Criteria:~* Active infection or other medical condition that would make prednisone (corticosteroid) use contraindicated~* Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone twice daily~* Pathological finding consistent with neuroendocrine carcinoma of prostate including small cell carcinoma~* Uncontrolled hypertension (systolic BP \>=160 mmHg or diastolic BP \>=95 mmHg; patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy)~* Active or symptomatic viral hepatitis or chronic liver disease, have a known infection with human immunodeficiency virus and/or hepatitis B virus or hepatitis C virus~* History of pituitary or adrenal dysfunction.~* Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease or cardiac ejection fraction measurement of \<50% at baseline~* Atrial fibrillation, or other cardiac arrhythmia requiring therapy~* Other malignancy within past 3 years (except basal or nonmetastatic squamous cell carcinoma of the skin)~* Known brain metastasis~* Prior therapy with abiraterone acetate or other CYP17 inhibitor(s), or investigational agent(s) targeting the androgen receptor for metastatic prostate cancer~* Prior therapy with ketoconazole for prostate cancer~* Surgery or local prostatic intervention within 30 days of the first dose~* Radiotherapy, chemotherapy, or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of Cycle 1 Day 1~* Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a National Cancer Institute-Common Terminology Criteria for Adverse Events grade of \<=1 (chemotherapy induced alopecia and grade 2 peripheral neuropathy is allowed)~* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Cycle 1 Day 1~* Anti-androgen treatment must not be given within 4 weeks (flutamide) or 6 weeks (bicalutamide or nilutamide) prior to Cycle 1 Day 1~* Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole) within 4 weeks prior to Cycle 1 Day 1~* Has known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients~* Has contraindications to the use of prednisone per local prescribing information~* Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abiraterone acetate plus prednisone (Type: EXPERIMENTAL): None
- Placebo plus prednisone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete